Pilot Study of Metformin in Head and Neck Squamous Cell Cancer and Its Effects on Stromal-epithelial Metabolic Uncoupling

Early Phase 1

Completed

• Conditions: Head and Neck Squamous Cell Cancer
• Interventions: Drug: Metformin

• Registration Number: NCT02083692
• Lead Sponsor: Sidney Kimmel Cancer Center at Thomas Jefferson University

Brief Summary

The purpose of this study is to assess the effect of metformin in tumor metabolism in patients with head and neck cancer by evaluating metformin's ability to decrease TOMM20 expression in squamous carcinoma cells and decrease MCT4 expression in fibroblasts.

Detailed Description

Not available

Study Timeline

• Study Start: 2013-09-05
• Study First Submitted: 2014-03-04
• Study First Submitted QC: 2014-03-06
• Study First Posted: 2014-03-11
• Primary Completion: 2016-05-09
• Study Completion: 2017-04-06
• Status Verified: 2024-02
• Last Update Submitted: 2024-02-20
• Last Update Posted: 2024-02-22

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 50

Inclusion Criteria

• Diagnosis of head and neck cancer biopsy proven, and who have a scheduled appointment for definitive resection of the tumor at TJUH
• Age ≥ 18 years of age and ≤80 years old.
• Newly diagnosed with HNSCC cancer.
• No prior therapy for HNSCC cancer is permitted for enrollment in the trial.
• All subjects must be able to comprehend and sign a written informed consent document.

Read More

Exclusion Criteria

• Pregnant or may become pregnant during metformin administration.
• On metformin for any reason during the preceding 4 weeks.
• Diabetic patients are eligible if they are not taking metformin, insulin or sulfonylureas.
• Received iodinated contrast dye less than 48 hours prior to screening meet a temporary exclusion criteria to receive metformin. These patients cannot start investigational metformin until 48 hours have elapsed from contrast administration. Subjects who are scheduled for iodinated contrast dye administration within 48 hours of definitive surgery are excluded.
• Plasma alanine aminotransferase greater than 40 IU/dL.
• Plasma aspartate aminotransferase greater than 45 IU/dL.
• Plasma creatinine level greater than 1.3 mg/dL.
• Plasma alkaline phosphatase greater than 190 IU/dL.
• Plasma bicarbonate less than 22 mEq/L or history of lactic or any other metabolic acidosis.
• History of congestive heart failure.
• Myocardial ischemia or peripheral muscle ischemia.
• Sepsis or severe infection.
• History of lung disease currently requiring any pharmacologic or supplemental oxygen treatment.
• Scheduled for definitive HNSCC cancer surgical resection less than two weeks from enrollment or greater than five weeks from enrollment.
• History of hepatic dysfunction or hepatic disease.
• Excessive alcohol intake which is defined in accordance with CDC definitions as more than 1 drink per day for women and more than 2 drinks per day for men.

All medications are permitted except those that are contraindicated with metformin under current FDA recommendations.

Read More

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Metformin	Metformin	-

Primary Outcome Measures

Name	Time	Method
Change in TOMM20 and MCT4 expression from tumor cells from date of biopsy and date of surgery	date of biopsy and date of surgery (9-28 days)

Trial Locations

Locations (1)

Thomas Jefferson University; 🇺🇸 Philadelphia, Pennsylvania, United States